|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammatory bowel disease and airway diseases显示文摘Airway diseases are the most commonly described lung manifestations of inflammatory bowel disease(IBD). However,the similarities in disease pathogenesis and the sharing of important environmental risk factors and genetic susceptibility suggest that there is a complex interplay between IBD and airway diseases. Recent evidence of IBD occurrence among patients with airway diseases and the higher than estimated prevalence of subclinical airway injuries among IBD patients support the hypothesis of a two-way association. Future research efforts should be directed toward further exploration of this association,as airway diseases are highly prevalent conditions with a substantial public health impact. | Maria Vutcovici Paul Brassard Alain Bitton | 2016 | World Journal of Gastroenterology2016，22，34： | 15 |
| 2 | Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology显示文摘 | Geoffrey C. Nguyen Charles N. Bernstein Alain Bitton Anthony K. Chan Anne M. Griffiths Grigorios I. Leontiadis William Geerts Brian Bressler J. Decker Butzner Marc Carrier Nilesh Chande John K. Marshall Chadwick Williams Clive Kearon | 2014 | Gastroenterology2014，，3： | 2 |
| 3 | Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study显示文摘BACKGROUND Biologic therapy resulted in a significant positive impact on the management of inflammatory bowel disease(IBD) however data on the efficacy and side effects of these therapies in the elderly is scant.AIM To evaluate retrospectively the drug sustainability, effectiveness, and safety of the biologic therapies in the elderly IBD population.METHODS Consecutive elderly(≥ 60 years old) IBD patients, treated with biologics [infliximab(IFX), adalimumab(ADAL), vedolizumab(VDZ), ustekinumab(UST)] followed at the McGill University Inflammatory Bowel Diseases Center were included between January 2000 and 2020.Efficacy was measured by clinical scores at 3, 6-9 and 12-18 mo after initiation of the biologic therapy. Patients completing induction therapy were included. Adverse events(AEs) or serious AE were collected during and within three months of stopping of the biologic therapy.RESULTS We identified a total of 147 elderly patients with IBD treated with biologicals during the study period, including 109 with Crohn’s disease and 38 with ulcerative colitis. Patients received the following biologicals: IFX(28.5%), ADAL(38.7%), VDZ(15.6%), UST(17%). The mean duration of biologic treatment was 157.5(SD = 148) wk. Parallel steroid therapy was given in 34% at baseline,19% at 3 mo, 16.3% at 6-9 mo and 6.5% at 12-18 mo. The remission rates at 3, 6-9 and 12-18 mo were not significantly different among biological therapies. Kaplan-Meyer analysis did not show statistical difference for drug sustainability(P = 0.195), time to adverse event(P = 0.158) or infection rates(P = 0.973) between the four biologics studied. The most common AEs that led to drug discontinuation were loss of response, infusion/injection reaction and infection.CONCLUSION Current biologics were not different regarding drug sustainability, effectiveness, and safety in the elderly IBD population. Therefore, we are not able to suggest a preferred sequencing order among biologicals. | Gustavo Drugg Hahn Jean-Frederic LeBlanc Petra Anna Golovics Panu Wetwittayakhlang Abdulrahman Qatomah Anna Wang Levon Boodaghians Jeremy Liu Chen Kiow Maryam Al Ali Gary Wild Waqqas Afif Alain Bitton Peter Laszlo Lakatos Talat Bessissow | 2022 | World Journal of Gastroenterology2022，28，33： | 1 |
| 4 | Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis显示文摘 | Alain Bitton Mark A. Peppercorn Donald A. Antonioli John L. Niles Samir Shah Athos Bousvaros Bernard Ransil Gary Wild Albert Cohen Michael D. deB Edwardes Anthony C. Stevens | 2001 | Gastroenterology2001，，1： | 1 |
| 5 | Combined budesonide and antibiotic therapy for active Crohn’s disease: A randomized controlled trial显示文摘 | A.Hillary Steinhart Brian G. Feagan Cindy J. Wong Margaret Vandervoort Shelley Mikolainis Kenneth Croitoru Ernest Seidman Desmond J. Leddin Alain Bitton Eric Drouin Albert Cohen Gordon R. Greenberg | 2002 | Gastroenterology2002，，1： | 1 |
| 6 | Psychological distress, social support, and disease activity in patients with inflammatory bowel disease显示文摘 | Maida J Sewitch Michal Abrahamowicz Alain Bitton Donald Daly Gary E Wild Albert Cohen Saul Katz Peter L Szego Patricia L Dobkin | 2001 | The American Journal of Gastroenterology2001，，5： | 1 |
| 7 | Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center:Access, resource utilization and outcomes显示文摘BACKGROUND Emergency situations in inflammatory bowel diseases(IBD)put significant burden on both the patient and the healthcare system.AIM To prospectively measure Quality-of-Care indicators and resource utilization after the implementation of the new rapid access clinic service(RAC)at a tertiary IBD center.METHODS Patient access,resource utilization and outcome parameters were collected from consecutive patients contacting the RAC between July 2017 and March 2019 in this observational study.For comparing resource utilization and healthcare costs,emergency department(ED)visits of IBD patients with no access to RAC services were evaluated between January 2018 and January 2019.Time to appointment,diagnostic methods,change in medical therapy,unplanned ED visits,hospitalizations and surgical admissions were calculated and compared.RESULTS 488 patients(Crohn’s disease:68.4%/ulcerative colitis:31.6%)contacted the RAC with a valid medical reason.Median time to visit with an IBD specialist following the index contact was 2 d.Patients had objective clinical and laboratory assessment(C-reactive protein and fecal calprotectin in 91%and 73%).Fast-track colonoscopy/sigmoidoscopy was performed in 24.6%of the patients,while computed tomography/magnetic resonance imaging in only 8.1%.Medical therapy was changed in 54.4%.ED visits within 30 d following the RAC visit occurred in 8.8%(unplanned ED visit rate:5.9%).Diagnostic procedures and resource utilization at the ED(n=135 patients)were substantially different compared to RAC users:Abdominal computed tomography was more frequent(65.7%,P<0.001),coupled with multiple specialist consults,more frequent hospital admission(P<0.001),higher steroid initiation(P<0.001).Average medical cost estimates of diagnostic procedures and services per patient was$403 CAD vs$1885 CAD comparing all RAC and ED visits.CONCLUSION Implementation of a RAC improved patient care by facilitating easier access to IBD specific medical care,optimized resource utilization and helped avoiding ED visits and subsequent hospitalizations. | Sofia Nene Lorant Gonczi Zsuzsanna Kurti Isabelle Morin Kelly Chavez Christine Verdon Jason Reinglas Rita Kohen Talat Bessissow Waqqas Afif Gary Wild Ernest Seidman Alain Bitton Peter Laszlo Lakatos | 2020 | World Journal of Gastroenterology2020，26，7： | 1 |
| 8 | Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis显示文摘 | Alain Bitton Mark A. Peppercorn Donald A. Antonioli John L. Niles Samir Shah Athos Bousvaros Bernard Ransil Gary Wild Albert Cohen Michael D. deB Edwardes Anthony C. Stevens | 2001 | Gastroenterology2001，，1： | 1 |
| 9 | Treatment of hospitalized adult patients with severe ulcerative colitis:Toronto Consensus Statements显示文摘 | Alain Bitton Donald Buie Robert Enns | 2012 | Am J Gastroenterol2012，107，： | 1 |
| 10 | A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn’s Disease显示文摘 | Brian Feagan John W. McDonald Remo Panaccione Robert A. Enns Charles N. Bernstein Terry P. Ponich Raymond Bourdages Donald G. MacIntosh Chrystian Dallaire Albert Cohen Richard Fedorak Pierre Pare Alain Bitton Fred Saibil Frank Anderson Allan Donner Cindy | 2008 | Gastroenterology2008，，1： | 1 |
| 11 | Combined budesonide and antibiotic therapy for active Crohn’s disease: A randomized controlled trial显示文摘 | A.Hillary Steinhart Brian G. Feagan Cindy J. Wong Margaret Vandervoort Shelley Mikolainis Kenneth Croitoru Ernest Seidman Desmond J. Leddin Alain Bitton Eric Drouin Albert Cohen Gordon R. Greenberg | 2002 | Gastroenterology2002，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员